Trials / Completed
CompletedNCT07012005
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of BPN14770 in Participants With Severe Renal Impairment and Healthy Control Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of BPN14770 in participants with severe renal impairment and those with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPN14770 | BPN14770 will be administered per schedule specified in the arm description. |
Timeline
- Start date
- 2025-08-25
- Primary completion
- 2025-12-15
- Completion
- 2025-12-15
- First posted
- 2025-06-10
- Last updated
- 2026-02-27
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07012005. Inclusion in this directory is not an endorsement.